鲁妥珠单抗
单克隆抗体 | |
---|---|
种类 | 完整抗体 |
目标 | HER3 |
临床资料 | |
其他名称 | RG7116 |
ATC码 |
|
识别信息 | |
CAS号 | 1448327-63-6 |
ChemSpider |
|
UNII | |
KEGG | |
化学信息 | |
化学式 | C6512H10064N1736O2052S44 |
摩尔质量 | 146,916.88 g·mol−1 |
鲁妥珠单抗(INN:lumretuzumab;开发代号:RG7116),或译鲁姆妥珠单抗,是一种人源化抗HER3单克隆抗体,设计用于治疗癌症。[1][2]
一项Ib/II期研究调查了在第一线治疗晚期或转移性鳞状非小细胞肺癌(sqNSCLC)患者时,鲁妥珠单抗与卡铂和紫杉醇联合使用的安全性和临床活性。[3]
参考资料
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Lumretuzumab, American Medical Association.
- ^ World Health Organization. International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 111 (PDF). WHO Drug Information. 2014, 28 (2).
- ^ Cejalvo, Juan-Miguel; Jacob, Wolfgang; Fleitas Kanonnikoff, Tania; Felip, Enriqueta; Navarro Mendivil, Alejandro; Martinez Garcia, Maria; Taus Garcia, Alvaro; Leighl, Natasha; Lassen, Ulrik; Mau-Soerensen, Morten; Adessi, Celine. A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer. ESMO Open. 2019, 4 (4). doi:10.1136/esmoopen-2019-000532 (英语).